Gilead Sciences - earnings after the bell
Gilead Sciences, Inc. is expected to report earnings after market close. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $1.53. The reported EPS for the same quarter last year was $1.37.
Gilead under performed the XBI - S&P Biotech ETF since Q3 2016. Horizontal support at $60.32 will be a key technical level to watch out for.
Gilead under performed the XBI - S&P Biotech ETF since Q3 2016. Horizontal support at $60.32 will be a key technical level to watch out for.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.